Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Tina Matthews-Hayes

Nurse Practitioner, Psychiatric/Mental Health Portland, OR Nurse Practitioner

NPI 1063726578 CMS profile 10440384

11740 Sw 68Th Pkwy Ste 11740Sw, Portland, OR 97223

Open in the dashboard

General payments

$786,688

1,263 records reported · program years 2021–2025

Research payments

$692

Paid to them · 2 records reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Tina Matthews-Hayes of Portland, OR is reported in the CMS Open Payments database as having received $786,688 across 1,263 general payments and $692 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner, Psychiatric/Mental Health profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $107,443 159
2024 General $176,082 228
2023 General $229,425 330
2022 General $173,047 320
2022 Research $692 2
2021 General $100,691 226

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Tina Matthews-Hayes
  • Nurse Practitioner, Psychiatric/Mental Health median
  • Middle half of Nurse Practitioner, Psychiatric/Mental Health
  • National median

In program year 2025, general payments to Tina Matthews-Hayes were reported at $107,443. Among 26,152 Nurse Practitioner, Psychiatric/Mental Health profiles paid that year, the median was $258 and the middle half received between $93 and $764.

Show as a table
Year Tina Matthews-Hayes Nurse Practitioner, Psychiatric/Mental Health median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $100,691 $166 $54–$482 $132
2022 $173,047 $195 $66–$559 $149
2023 $229,425 $233 $82–$673 $160
2024 $176,082 $236 $84–$688 $164
2025 $107,443 $258 $93–$764 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $622,880 882 payments
  2. Janssen Pharmaceuticals, Inc $71,280 98 payments
  3. Neurocrine Biosciences, Inc. $62,583 94 payments
  4. Biogen, Inc. $12,688 5 payments
  5. Allergan Inc. $6,682 8 payments
  6. Teva Pharmaceuticals USA, Inc. $5,719 65 payments
  7. E.R. Squibb & Sons, L.L.C. $2,108 11 payments
  8. Otsuka Pharmaceutical Development & Commercialization, Inc. $1,000 1 payment
  9. Alkermes, Inc. $385 12 payments
  10. ITI, Inc. $365 9 payments
  11. Other $998 78 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $546,837 279 payments
  2. Travel and Lodging $157,113 360 payments
  3. Consulting Fee $63,996 37 payments
  4. Food and Beverage $18,687 585 payments
  5. Education $55 2 payments
Products named General payments · program years 2021–2025
  1. VRAYLAR Neuroscience $525,170 761 payments
  2. VRAYLAR Neuroscience $97,869 114 payments
  3. SPRAVATO $71,220 95 payments
  4. INGREZZA Neuropsychiatry $57,338 77 payments
  5. INGREZZA Neurology $5,223 16 payments
  6. UZEDY $5,042 37 payments
  7. ABILIFY ASIMTUFII $1,164 11 payments
  8. UBRELVY $954 3 payments
  9. QULIPTA $920 2 payments
  10. BOTOX $920 2 payments
  11. Other $3,906 168 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2021–2025
  1. AbbVie, Inc. $692 2 payments

Prescribing to Medicare patients

Part D · data year 2024 · 14 drugs

Part D claims

291

Median for Nurse Practitioner: 389

Drug cost

$41,163

Median for Nurse Practitioner: $21,885

Branded share of claims

24.7%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Vraylar Cariprazine Hcl Brand 25 $36,316
Desvenlafaxine Succinate Er Desvenlafaxine Succinate Brand 19 $2,114
Divalproex Sodium Er Divalproex Sodium Brand 16 $751
Duloxetine Hcl Generic 15 $465
Mirtazapine Generic 13 $345
Venlafaxine Hcl Er Venlafaxine Hcl Brand 12 $207
Clonazepam Generic 47 $181
Quetiapine Fumarate Generic 26 $172
Lamotrigine Generic 22 $155
Propranolol Hcl Generic 22 $137

The 10 drugs with the highest cost, of 14 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 8 billing codes

Paid by Medicare

$11,845

Medicare's payments for the services billed

Medicare patients

26

Average age 68

Services billed

187

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Depression 69%
Arthritis 58%
High blood pressure 54%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 12 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
$126,779 25 —
SPRAVATO
$28,864 — —
INGREZZA
$15,471 — —
ABILIFY ASIMTUFII
$1,064 — —
UZEDY
$205 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 12 in the dashboard with a free account

Records

1,265 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Psychiatric/Mental Health in Oregon

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record